论文部分内容阅读
目的初步探讨胰腺癌病灶的18F-FDG摄取程度(SUV)与手术切除标本的血管内皮生长因子(VEGF)表达及微血管密度(MVD)之间的关系,考察SUV是否能够于疗前在体评估胰腺癌的血管生成状态。方法纳入2008年5月至2011年9月于我科行PET-CT检查后行手术切除的10例胰腺导管腺癌患者,术前均未行放疗或化疗。记录PET-CT图像中病灶的最大标准摄取值(SUVmax),并使用免疫组织化学染色检查胰腺癌标本的MVD及VEGF表达。结果 10例胰腺癌病灶的中位SUVmax为4.7(3.3~5.9),中位MVD为67(49~110),VEGF(-)4例,VEGF(+)3例,VEGF(++)3例。取中位SUVmax=4.7为界值点分组对比可知,VEGF(++)患者的SUVmax高于VEGF(+)/(-)患者,且MVD计数较高与SUVmax偏高存在一定正相关趋势。结论本组小样本结果初步表明,胰腺导管腺癌的SUVmax越高,发生转移的可能性越大。SUVmax与VEGF表达和MVD计数存在正相关趋势的可能,初步提示18F-FDG PET-CT检查有可能于疗前在体评估胰腺癌的血管生成状态,有望为临床是否行分子靶向治疗提供更多有价值的信息。
Objective To investigate the relationship between 18F-FDG uptake (SUV) in pancreatic cancer and the expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in surgical specimens and to investigate whether SUV can assess pancreatic Angiogenesis status of cancer. Methods A total of 10 patients with pancreatic ductal adenocarcinoma who underwent surgical resection after PET-CT examination from May 2008 to September 2011 were included in this study. All patients underwent radiotherapy or chemotherapy before surgery. The maximal standard uptake value (SUVmax) of lesions in PET-CT images was recorded and MVD and VEGF expression in pancreatic cancer specimens were examined by immunohistochemical staining. Results The median SUVmax was 4.7 (3.3-5.9), the median MVD was 67 (49-110), VEGF (-) was 4, VEGF (+) 3 and VEGF . Taking the median SUVmax = 4.7 as the cut-off value, we found that the SUVmax of patients with VEGF (++) was higher than that of patients with VEGF (+) / (-), and there was a positive correlation between the higher MVD and higher SUVmax. Conclusion The results of this small group of samples initially showed that the higher the SUVmax of pancreatic ductal adenocarcinoma, the greater the possibility of metastasis. There is a positive correlation between SUVmax and VEGF expression and MVD counts. It is suggested that 18F-FDG PET-CT may assess the angiogenesis status of pancreatic cancer in vivo before treatment, and it is expected to provide more clinical options for molecular targeted therapy Valuable information.